Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

• DOI: 10.1007/s00280-020-04073-5
• Publication Date: 2020-04-20T15:04:29Z
• Authors: Geraldine O.’Sull...; Lihua Wang; Jennifer Zlott; Lamin Juwara; Joseph M. Covey; Jan H. Beumer; Mihaela C. Cristea; Edward M. Newman; Stephen Koehler; Jorge J. Nieva; Agustin A. Garcia; David R. Gandara; Brandon Miller; Sonny Khin; Sarah B. Miller; Seth M. Steinberg; Larry Rubinstein; Ralph E. Parchment; Robert J. Kinders; Richard L. Piekarz; Shivaani Kummar; Alice P. Chen; James H. Doroshow
• Keywords: DNA (Cytosine-5-)-Methyltransferase 1; Male; Carcinoma, Transitional Cell; Urologic Neoplasms; Antineoplastic Agents; Cell Count; Middle Aged; Neoplastic Cells, Circulating; Deoxycytidine; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; 0302 clinical medicine; Pharmacogenetics; Tetrahydrouridine; Humans; Original Article; Administration, Intravenous; Female; Cyclin-Dependent Kinase Inhibitor p16

Abstract Purpose Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this combination in patients with advanced solid tumor types for which tumor suppressor gene methylation is potentially prognostic. To obtain pharmacodynamic evidence for DNMT inhibition by FdCyd, we developed a novel method for detecting expression of tumor suppressor protein p16/INK4A in circulating tumor cells (CTCs).

Methods Patients in histology-specific strata (breast, head and neck [H&N], or non-small cell lung cancers [NSCLC] or urothelial transitional cell carcinoma) were administered FdCyd (100 mg/m2) and THU (350 mg/m2) intravenously 5 days/week for 2 weeks, in 28-day cycles, and progression-free survival (PFS) rate and objective response rate (ORR) were evaluated. Blood specimens were collected for CTC analysis.

Results Ninety-three eligible patients were enrolled (29 breast, 21 H&N, 25 NSCLC, and 18 urothelial). There were three partial responses. All strata were terminated early due to insufficient responses (H&N, NSCLC) or slow accrual (breast, urothelial). However, the preliminary 4-month PFS rate (42%) in the urothelial stratum exceeded the predefined goal—though the ORR (5.6%) did not. An increase in the proportion of p16-expressing cytokeratin-positive CTCs was detected in 69% of patients evaluable for clinical and CTC response, but was not significantly associated with clinical response.

Conclusion Further study of FdCyd + THU is potentially warranted in urothelial carcinoma but not NSCLC or breast or H&N cancer. Increase in the proportion of p16-expressing cytokeratin-positive CTCs is a pharmacodynamic marker of FdCyd target engagement.